Clinical trial
Neoadjuvant Therapy for Breast Cancer Based on Patient-derived Tumor-like Cell Clusters Advanced Drug Sensitization Regimens: a Phase II Randomized Controlled Clinical Study
NCT05103293 is registered in ClinicalTrials.gov with Zhejiang Cancer Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Neoadjuvant Therapy for Breast Cancer Based on Patient-derived Tumor-like Cell Clusters Advanced Drug Sensitization Regimens: a Phase II Randomized Controlled Clinical Study
- Lead sponsor
- Zhejiang Cancer Hospital
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 1, 2021
- Completion date
- December 10, 2023
- Enrollment
- 86 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.